Regeneron
Immuneering Partners with Regeneron to Study Combined MEK, PD-1 Inhibitor Therapy in Solid Tumors
Regeneron will supply Libtayo within an ongoing Phase II trial of Immuneering's MEK inhibitor.
Sonoma Bio Receives $45M Milestone Payment From Regeneron
The payment was triggered when Sonoma achieved a milestone related to an unspecified autologous Tregcell therapy it is developing with Regeneron.
Roche PD-L1 Assay Nabs Expanded CE Mark as CDx for Libtayo, Chemotherapy Combo
The Ventana assay previously received CE marking for identifying patients with lung cancer who may benefit from treatment with Libtayo.
Regeneron Gene Therapy Restores Hearing in Infant With Genetic Form of Deafness, Data at ASGCT Show
Premium
The 10-month-old patient was treated with DB-OTO, a gene therapy developed by Decibel Therapeutics, which Regeneron acquired last year.
Mammoth Biosciences to Receive $100M Upfront in Therapeutic CRISPR Gene Editing Deal With Regeneron
Mammoth is also eligible to receive up to $370 million per target in development, as well as regulatory and commercial milestone payments and royalties from product sales.